Document:

Field-Of-Use Non-Exclusive License Agreement

 Exhibit 10.11 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934,
as amended. 
 FIELD-OF-USE NON-EXCLUSIVE
LICENSE AGREEMENT 
 FOR YEAST-BASED
DELIVERY VEHICLES 
 BETWEEN 

WASHINGTON RESEARCH FOUNDATION 

AND 
 GLOBEIMMUNE, INC. 
  

	 	1.	DEFINITIONS 

	 	2.	GRANT 

	 	3.	PAYMENTS AND ROYALTIES 

	 	4.	REPORTS AND REMITTANCES 

	 	5.	AUDIT 

	 	6.	INFRINGEMENT ACTIONS 

	 	7.	TERM AND TERMINATION 

	 	8.	RIGHTS AND DUTIES UPON TERMINATION 

	 	9.	PATENT PROSECUTION AND MAINTENANCE 

	 	10.	INSURANCE 

	 	11.	TRADEMARKS, TRADE NAMES AND PATENT MARKING 

	 	12.	DILIGENCE OBLIGATIONS 

	 	13.	ASSIGNABILITY 

	 	14.	WARRANTIES, REPRESENTATIONS AND INDEMNITIES 

	 	15.	NOTICES 

	 	16.	GOVERNING LAWS 

	 	17.	ARBITRATION AND JURISDICTION 

	 	18.	ATTORNEYS FEES 

	 	19.	SEPARABILITY 

	 	20.	CONFIDENTIALITY 

	 	21.	MISCELLANEOUS 

  

			
	APPENDIX A	  	PATENT STATUS
	APPENDIX B	  	GLOBEIMMUNE REPORT

  
 Page 1

 [*] = Certain confidential information contained in this document, marked by brackets, is filed
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 FIELD-OF-USE
NON-EXCLUSIVE LICENSE AGREEMENT 
 FOR
YEAST-BASED DELIVERY VEHICLES 
 BETWEEN

 WASHINGTON RESEARCH FOUNDATION 

AND 
 GLOBEIMMUNE, INC. 
 This agreement
(“AGREEMENT”) is made and is effective on the date of the last PARTY to sign below (“EFFECTIVE DATE”) by and between Washington Research Foundation (“WRF”), a non-profit Washington Corporation having administrative
offices at 2815 Eastlake Avenue East, Suite 300, Seattle, Washington U.S A. 98102 and GLOBEIMMUNE, INC., having administrative offices at 1899 Gaylord St., Denver, CO 80206. 
 WHEREAS, WRF is the owner by assignment from the University of Washington, of certain technology generally characterized as “Expression of Polypeptides in Yeast” (“TECHNOLOGY”);

 WHEREAS, WRF desires that the TECHNOLOGY be developed and utilized to the fullest extent so that the benefits can be enjoyed by the general
public; 
 WHEREAS, the TECHNOLOGY is covered by certain PATENT RIGHTS, defined below, and those PATENT RIGHTS are owned jointly by WRF and
GENENTECH, Incorporated (“GENENTECH”), a company having administrative offices at 1 DNA. Way, South San Francisco, California U.S.A. 94080; 
 WHEREAS, WRF and GENENTECH are prosecuting, administering, and maintaining the patents described in Appendix A and WRF is acting as the sole and exclusive licensor of the PATENT RIGHTS to be granted by
this AGREEMENT; 
 WHEREAS, GLOBEIMMUNE has expressed a commitment to commercialize yeast-based delivery vehicles
manufactured under PATENT RIGHTS; and 
 WHEREAS, WRF is willing to grant such rights. 
 NOW, THEREFORE, for and in consideration of the covenants, conditions, and undertakings set forth below, it is agreed by and between the PARTIES as follows: 

 

	1.	DEFINITIONS 

  

	1.1	“PATENT RIGHTS” shall mean WRF’ s rights to the patents listed in Appendix A, attached hereto and incorporated herein, and any and all existing and
future divisions, continuations or reissues arising therefrom or issued thereon, and rights derived from corresponding foreign patents. 

  

	1.2	 “AFFILIATE” shall mean (i) any corporation or other business entity of which fifty percent (50%) or more of the equity or other
ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by 

  
 Page 2

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	 	
GLOBEIMMUNE; or (ii) any corporation, firm, partnership or other entity, whether de jure or de facto, which directly or indirectly owns, controls or
holds fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) or more of the equity or profits, the voting stock or the general partnership interest, of
GLOBEIMMUNE; or (iii) any corporation or other business entity of which fifty percent (50%) or more of the equity or other ownership interests representing the equity, the voting stock or general partnership
interest are owned, controlled or held, directly or indirectly, by a corporation or other business entity described in (i) or (ii), and any person, firm, partnership, corporation or other entity, including joint ventures or joint businesses,
actually controlled by, controlling or under common control with GLOBEIMMUNE. 

  

	1.3	“PARTY” shall mean GLOBEIMMUNE or WRF, and when used in plural shall mean GLOBEIMMUNE and WRF.

  

	1.4	“THIRD PARTY” or “THIRD PARTIES” shall mean individuals, corporate or other entities other than WRF, GLOBEIMMUNE,
SUBLICENSEES or AFFILIATES, or employees of such entities 

  

	1.5	“TERRITORY” shall mean all countries of the world in which WRF has PATENT RIGHTS. 

 

	1.6	“FIELD OF USE” shall mean [*] 

  

	1.7	“LICENSED PRODUCT” shall mean a composition made, used, offered for sale, sold, or imported in the TERRITORY and where, but for the license granted under this
AGREEMENT, such making, using, offering for sale, selling or importing would infringe a VALID CLAIM. 

  

	1.8	“SUBLICENSE” shall mean any agreement which includes the present, future, or contingent transfer by GLOBEIMMUNE to a THIRD PARTY
of a right under the PATENT RIGHTS in the FIELD OF USE to make, have made, use, offer for sale, sell, have sold, import or otherwise distribute LICENSED PRODUCT granted under this AGREEMENT, in whole or in part. A SALE is not a SUBLICENSE.

  

	1.9	“SUBLICENSEE” shall mean a THIRD PARTY receiving a SUBLICENSE under this AGREEMENT. 

 

	1.10	“SALE” shall mean the sale or other transfer by GLOBEIMMUNE, an AFFILIATE or a SUBLICENSEE to a THIRD PARTY of any right of
ownership of a LICENSED PRODUCT, including sale or other transfer of a LICENSED PRODUCT for use in preclinical or clinical development. 

  

	1.11	“NET SALES” shall mean [*]. 

  

	1.12	“VALID CLAIM shall mean a claim of an issued and unexpired patent within the PATENT RIGHTS, which has not been held unenforceable, unpatentable or invalid by an
unappealed or unappealable judgment from a court or other governmental agency of competent jurisdiction, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer. 

  
 Page 3

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	2.	GRANT 

  

	2.1	Subject to the terms and conditions of this Agreement, WRF hereby grants to GLOBEIMMUNE non-exclusive license under PATENT RIGHTS to
develop, use, make, have made, market, offer for sale, sell, have sold or import LICENSED PRODUCTS in the FIELD OF USE. 

  

	2.2	No rights are granted hereby under patent rights, copyrights or trade secret rights owned by WRF and/or GENENTECH other than as specifically provided in
Article 2. 

  

	2.3	GLOBEIMMUNE shall have the right to enter into SUBLICENSES [*]. GLOBEIMMUNE shall provide WRF with a copy of
each signed SUBLICENSE within 30 days of its execution, provided, however, that such copy may be redacted to remove confidential, proprietary information of GLOBEIMMUNE. The terms of such SUBLICENSES shall provide for
royalty obligations no less than those laid out in Paragraph 3.2 below, and reporting and audit obligations no less than those laid out in Articles 4 and 5 below. 

 

	2.4	No rights are granted hereby to makes SALES of LICENSED PRODUCTS that are not formulated, packaged and intended for administration to human or animal subjects.

  

	2.5	WRF agrees that WRF will not assert against GlobeImmune, AFFILIATES or SUBLICENSEES any claim of infringement under the PATENT RIGHTS with respect to a LICENSED PRODUCT
for which rights have been granted under Article 2 and for which a royalty has been paid in accordance with the provisions of Article 3. 

  

	3.	PAYMENTS AND ROYALTIES 

 

	3.1	[*] 

  

	3.2	Royalties: 

  

	 	(i)	GLOBEIMMUNE shall pay WRF [*] of NET SALES on compositions that GLOBEIMMUNE has affirmatively identified [*]
to WRF as LICENSED PRODUCTS. 

  

	 	(ii)	Should arbitration be required to establish that a composition is LICENSED PRODUCT, the royalty rate on NET SALES of such composition shall be the greater of [*] or [*]

  

	 	(iii)	Payment of royalties to WRF [*]. 

  

	3.3	[*] 

  

	3.4	[*] 

  

	3.5	[*] 

  

	3.6	[*] 

  

	3.7	Exchange Rates: All payments to WRF shall be made in U.S. Dollars. The exchange rate shall be the inter bank rate listed at www.oanda.com (or other
mutually-agreeable site) for the last business day of the calendar half-year in which the royalty payment accrues. NET SALES received by GLOBEIMMUNE or AFFILIATES in U.S. Dollars will not be the subject of currency
conversion. 

  
 Page 4

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	3.8	Interest on Late Payments: All payments and royalties due WRF under this AGREEMENT not received when due shall be subject to interest charged at [*] or the
maximum rate permissible under the law, whichever is lower. Payment of such interest shall not limit WRF from exercising any other rights it may have as a consequence of the lateness of any payment. Payments received by WRF shall be applied first to
the outstanding interest due and then to the outstanding principal due. 

  

	3.9	A judgment from a court of competent jurisdiction from which no appeal can be or is taken, which renders all the PATENT RIGHTS invalid, shall not affect any obligation
accrued hereunder up to the date upon which the last right of appeal has expired or been exhausted. After such a judgment, and the expiration of all opportunities to appeal, no royalties or other monetary obligations will accrue for further sales of
(products formerly known as) LICENSED PRODUCTS in that part of the TERRITORY affected by the judgment. 

  

	4.	REPORTS AND REMITTANCES 

 

	4.1	WRF, for a period of [*] from receipt of any reports or remittances, shall consider such reports and remittances received from GLOBEIMMUNE
as confidential as provided under Paragraph 20, whether or not marked as such. WRF shall provide the University of Washington and GENENTECH with collective or consolidated dollar and NET SALES and royalty payment information from all
licensees under PATENT RIGHTS and shall not disclose GLOBEIMMUNE’S individual data, reports or remittances. 

 

	4.2	On or before March 1 of each year, GLOBEIMMUNE shall provide to WRF reports describing the progress made by
GLOBEIMMUNE, AFFILIATES and SUBLICENSEES in developing compositions made using genetically modified yeast during the prior calendar year. GLOBEIMMUNE, AFFILIATES and SUBLICENSEES shall
report all compositions made in genetically modified yeast along with information sufficient for WRF to establish that such compositions fall (or do not fall) within the PATENT RIGHTS and are therefore (or are not) LICENSED PRODUCTS.

 GLOBEIMMUNE shall report to WRF the Date of First SALE or commercial use of each
LICENSED PRODUCT within sixty (60) days. On or before March 1 and September 1 of each year, GLOBEIMMUNE shall provide to WRF a true accounting of all LICENSED PRODUCTS manufactured, imported and
inventoried, and NET SALES, and at the same time shall pay all royalties due. Such reports shall include a list of current AFFILIATES and SUBLICENSEES and must be detailed on a product-by-product and country-by-country basis. All deductions to the
gross amounts invoiced, royalties, fees or other consideration must be supported by detailed information provided in the semi-annual report. GLOBEIMMUNE shall use a reporting form attached hereto as Appendix B and
incorporated herein. GLOBEIMMUNE’s responsible financial officer shall execute the reports. 
  

	4.3	WRF shall provide to GLOBEIMMUNE a written report describing changes to the status of PATENT RIGHTS within sixty (60) days of such
changes. 

  
 Page 5

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	5.	AUDIT 

 WRF
shall have the right, through a certified public accountant reasonably acceptable to GLOBEIMMUNE, and with reasonable advance notice in writing, to audit the books and records (including the unredacted and executed
SUBLICENSE agreements) of GLOBEIMMUNE, AFFILIATES and SUBLICENSEES and to conduct personal interviews, as may be reasonably necessary, to confirm the accuracy and completeness of the information provided in
Section 4.2 once per calendar year during regular business hours during the life of this AGREEMENT and for [*] after its termination; provided, however, that such audit shall not cover records for more than the preceding [*] and provided
further that the accountant shall report to WRF only as to the accuracy and completeness of the information provided under Section 4.2 as well as corrections, areas of dispute, inconsistencies, denials of access to information or cooperation,
together with sufficient background information to allow WRF to evaluate and resolve any issues identified by the audit. GLOBEIMMUNE, AFFILIATES and SUBLICENSEES shall cooperate in any such audit so that the auditors
may reasonably perform the audit, and shall pay WRF any monies owing within thirty (30) days of the completion of the audit. [*]. 
  

	6.	INFRINGEMENT ACTIONS 

 In the event that GLOBEIMMUNE becomes aware of actual or threatened infringement of PATENT RIGHTS, GLOBEIMMUNE shall promptly notify WRF in
writing. WRF shall have the sole right to deal with infringing parties. 
  

	7.	TERM AND TERMINATION 

  

	7.1	This AGREEMENT shall be in full force and effect from the EFFECTIVE DATE and shall remain in effect in each country in the TERRITORY so long as any VALID CLAIM exists
or unless otherwise terminated by operation of law or pursuant to the terms and conditions of this AGREEMENT. 

  

	7.2	Termination of this AGREEMENT due to the abandonment or invalidation of the last remaining VALID CLAIM shall enable GLOBEIMMUNE to
continue commercializing (formerly) LICENSED PRODUCTS without accrual of any further payments due to WRF. 

  

	7.3	GLOBEIMMUNE shall have the right to terminate this AGREEMENT by giving written notice to WRF, effective immediately upon receipt.

  

	7.4	WRF may terminate this AGREEMENT if GLOBEIMMUNE shall file in any court pursuant to any statute of the United States, any individual state
or foreign country, a petition in bankruptcy, insolvency, reorganization or for the appointment of a receiver or trustee of GLOBEIMMUNE or of its assets. In the event WRF ceases to operate, the ownership of this
AGREEMENT immediately and automatically reverts to the University of Washington as described in WRF’s charter and WRF will assign this AGREEMENT and all of its interests in PATENT RIGHTS to the University of Washington.

  
 Page 6

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	7.5	Failure of either PARTY to comply with any of the material obligations contained in this AGREEMENT shall entitle the other PARTY to give the breaching PARTY a notice
specifying the nature of the breach claimed and the action required to correct the breach. If such breach is not corrected within [*] after the receipt of such notice, the notifying PARTY shall be entitled, without prejudice to any of its other
rights conferred on it by this AGREEMENT, in addition to any other remedies available to it by law, to terminate this AGREEMENT by giving written notice effective immediately upon receipt. 

 

	7.6	The parties to this AGREEMENT shall be excused from any performance required hereunder if and only so long as such performance is rendered impossible or unfeasible due
to any acts of God, catastrophes, or other major events beyond their reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor
disputes; and floods, fires, explosions, or other natural disasters. 

  

	7.7	SUBLICENSES shall terminate immediately on the termination of this AGREEMENT. WRF shall negotiate in good faith with SUBLICENSEES desiring direct licenses in the event
that this AGREEMENT is terminated. 

  

	8.	RIGHTS AND DUTIES UPON TERMINATION 

 

	8.1	Upon termination of this AGREEMENT, WRF shall have the right to retain any sums already paid by GLOBEIMMUNE and
GLOBEIMMUNE shall pay to WRF all sums accrued hereunder. 

  

	8.2	Upon the termination of this AGREEMENT, GLOBEIMMUNE shall inform WRF of the amount of LICENSED PRODUCTS manufactured, imported or
inventoried by GLOBEIMMUNE and AFFILIATES as of sixty (60) days after the termination date. GLOBEIMMUNE and AFFILIATES shall be permitted to make SALES within one year of termination
of this AGREEMENT and shall pay WRF the earned royalty on these NET SALES, as required under Section 3.2. 

  

	8.3	Only the following Articles shall survive termination of this AGREEMENT: 1, 3.8, 4, 5, 7.2, 7.7, 8, 10, 11, 14, 15, 16, 17, 18, 19, 20, and 21.

  

	9.	PATENT PROSECUTION AND MAINTENANCE 

GLOBEIMMUNE shall not be responsible for the costs of patent prosecution and maintenance. 

 

	10.	INSURANCE 

  

	10.1	GLOBEIMMUNE, AFFILIATES and SUBLICENSEES shall maintain general liability insurance of at least [*].
GLOBEIMMUNE, AFFILIATES and SUBLICENSEES must declare whether the insurance is provided on a “claims-made” form and must notify WRF if coverage is cancelled. Upon WRF’s request,
GLOBEIMMUNE, AFFILIATES and SUBLICENSEES shall provide WRF annually with such certificates of insurance. Failure to maintain continuous coverage as required by this AGREEMENT shall be deemed a material breach.

  
 Page 7

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	10.2	GLOBEIMMUNE, AFFILIATES and SUBLICENSEES shall, prior to any human testing of LICENSED PRODUCTS, obtain product liability or clinical
trial insurance, as appropriate, in the amount of [*] or such greater amounts as GLOBEIMMUNE AFFILIATES and SUBLICENSEES may obtain from time to time, which names WRF, GENENTECH and the University of
Washington as additional insureds. GLOBEIMMUNE shall provide WRF annually with such certificates of insurance. 

  

	11.	TRADEMARKS, TRADE NAMES AND PATENT MARKING 

 

	11.1	Nothing contained in this AGREEMENT shall be construed as conferring any right to use in advertising, publicity or other promotion activities any name, trade name,
trademark or other designation of either PARTY hereto including any contraction, abbreviation or simulation of any of the foregoing, unless the express written permission of the other PARTY has been obtained. The use of the names Washington Research
Foundation, WRF, University of Washington, or GENENTECH by GLOBEIMMUNE and AFFILIATES is expressly prohibited. 

 

	11.2	GLOBEIMMUNE shall mark, and shall require AFFILIATES and SUBLICENSEES to mark, each LICENSED PRODUCT made and sold with an appropriate
patent marking identifying any issued patent under PATENT RIGHTS. 

  

	12.	DILIGENCE OBLIGATIONS 

 GLOBEIMMUNE shall, directly or through AFFILIATES or SUBLICENSEES, use [*] and shall demonstrate progress in developing, marketing, and selling LICENSED PRODUCTS. 

 

	13.	ASSIGNABILITY 

  

	13.1	WRF shall have the right to assign this AGREEMENT. WRF shall inform GLOBEIMMUNE within sixty (60) days of such assignment.

  

	13.2	GLOBEIMMUNE shall have the right to assign this AGREEMENT only to AFFILIATES or to a successor by merger or sale of all or of
substantially all of GLOBEIMMUNE’s assets in a manner such that the assignor shall remain liable and responsible for the performance and observance of all its duties and obligations hereunder. This AGREEMENT shall
be binding upon the successors and permitted assignees of GLOBEIMMUNE. Any assignment not in accordance with this paragraph shall be voidable at WRF’s election. GLOBEIMMUNE shall
notify WRF within sixty (60) days of the assignment of this AGREEMENT. 

  

	14.	WARRANTIES, REPRESENTATIONS AND INDEMNITIES 

 

	14.1	WRF warrants that it has the lawful right to grant the license set forth herein. 

  
 Page 8

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	14.2	Nothing in this AGREEMENT shall be construed as: 

  

	 	(i)	a warranty or representation by WRF as to the validity, enforceability or scope of any patent application or patent included in PATENT RIGHTS; 

 

	 	(ii)	a warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this AGREEMENT is or will be free from infringement
of patents of THIRD PARTIES; 

  

	 	(iii)	an obligation to bring or prosecute actions or suits against THIRD PARTIES for infringement; 

 

	 	(iv)	an obligation to furnish any manufacturing or technical information; or 

  

	 	(v)	a warranty by WRF of the fitness of this technology to manufacture LICENSED PRODUCTS. 

 

	14.3	GLOBEIMMUNE, AFFILIATES and SUBLICENSEES shall indemnify, hold harmless and defend WRF, the University of Washington,
GENENTECH and their officers, employees and agents against any and all claims, suits, losses, damage costs, fees, and expenses resulting from or arising out of the manufacture, use or SALE of LICENSED PRODUCTS by
GLOBEIMMUNE, AFFILIATES and SUBLICENSEES or its customers, including but not limited to any damages, losses or liabilities whatsoever with respect to death or injury to any person and damage to any property arising from
the possession, use or operation of the LICENSED PRODUCTS by GLOBEIMMUNE, AFFILIATES or SUBLICENSEES or their customers, in any manner whatsoever, provided WRF gives prompt written notice to
GLOBEIMMUNE of any claim or suit for which indemnification hereunder is sought. However, GLOBEIMMUNE, AFFILIATES and SUBLICENSEES shall not indemnify any party -WRF,
GENENTECH or the University of Washington - for claims that result from the gross negligence, or willful misconduct of that party. 

  

	15.	NOTICES 

 Any payment,
notice or other communication required from either PARTY, if delivered in writing, shall be sent by first-class mail or commercial carrier with return receipt requested to the respective address given below, or to such other address as either PARTY
shall designate by written notice. If delivered via electronic communication, the sending PARTY shall also promptly confirm via U.S. Mail. 
  

			
	 In the case of GLOBEIMMUNE
 GlobeImmune, Inc.
 12635 E. Montview Blvd.
 Aurora, CO 80010
 Attention: Chief Executive Officer

Facsimile: (720) 859-4065
	  	 In the case of WRF

Washington Research Foundation
 2815 Eastlake
Avenue East, Suite 300
 Seattle, WA 98102
 Attention: President
 Facsimile: (206) 336-5615

with a copy to: Director of Licensing

  
 Page 9

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	16.	GOVERNING LAWS 

 This AGREEMENT shall be interpreted and construed in accordance with the laws of the State of Washington, Country of the United States of America. 

 

	17.	ARBITRATION AND JURISDICTION 

 The PARTIES shall first employ reasonable efforts to resolve controversies or disputes between them without resort to arbitration or other legal action. In the event that the PARTIES are not able to
resolve any controversy or dispute, such controversy or dispute will be resolved by arbitration in accordance with rules applied by the CPR Institute of Dispute Resolution, and shall be conducted in Seattle, Washington U.S.A. Arbitration awards may
be filed in and enforced in U.S. Federal Court or any other court of competent jurisdiction. 
  

	18.	ATTORNEYS FEES 

 In the event of any arbitration or legal action between the PARTIES hereto arising from this AGREEMENT, the prevailing PARTY shall be entitled to reimbursement from the other PARTY of all out-of-pocket
costs and reasonable legal fees associated with such arbitration or legal action. 
  

	19.	SEPARABILITY 

  

	19.1	In the event that any part of this AGREEMENT shall be held illegal, void or ineffective, the remaining portions hereof shall remain in full force and effect.

  

	19.2	If any of the terms or provisions of this AGREEMENT are, or become in conflict with any applicable statute, rule or law, then such terms or provisions shall he deemed
inoperative only to the extent that they may conflict therewith and shall be modified or deemed modified to conform with such statute, rule or law. 

  

	19.3	In the event that any of the terms and conditions of this AGREEMENT is materially altered as a result of Paragraphs 19.1 and 19.2, the PARTIES shall renegotiate those
terms and conditions to resolve any inequities. 

  

	20.	CONFIDENTIALITY 

 Except to the extent expressly authorized in this AGREEMENT, for the term of this AGREEMENT, and for [*] thereafter, GLOBEIMMUNE and WRF shall keep reasonably confidential
all material provided by the other PARTY and marked confidential, and shall not publish or otherwise disclose such information and shall not use such confidential information except to the extent that it can be established by WRF or by
GLOBEIMMUNE by competent proof that such information: 
  

	 	(i)	was already known to the receiving party, either GLOBEIMMUNE or WRF, other than under an obligation of confidentiality, at the time of
disclosure by the other PARTY; 

  
 Page 10

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

	 	(ii)	was generally available to the public or otherwise part of the public domain at the time of its disclosure to WRF or GLOBEIMMUNE;

  

	 	(iii)	became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of WRF or
GLOBEIMMUNE in breach of this AGREEMENT; 

  

	 	(iv)	was subsequently lawfully disclosed to WRF or GLOBEIMMUNE by a THIRD PARTY; 

 

	 	(v)	was disclosed by WRF or GLOBEIMMUNE as reasonably necessary in prosecuting or defending litigation, or complying with applicable
governmental regulations. 

 For purposes of clarification, notwithstanding anything to the contrary,
GLOBEIMMUNE and WRF each will apply a standard of care with respect to material and information received from the other PARTY consistent with and no less restrictive than the care it applies to its own confidential,
proprietary material and information. 
  

	21.	MISCELLANEOUS 

  

	21.1	The headings of the several sections and the Summary Tables below are inserted for convenience and reference only and are not intended to be a part of, or to affect the
meaning or interpretation of, this AGREEMENT. 

  

	21.2	This AGREEMENT shall not be binding upon the PARTIES until it has been signed by or on behalf of each PARTY, in which event, it shall be effective as of the EFFECTIVE
DATE. 

  

	21.3	No amendment or modification hereof shall be valid or binding upon the PARTIES unless made in writing and signed by or on behalf of each party.

  

	21.4	This AGREEMENT shall embody the entire understanding of the PARTIES and shall supersede all previous communications, representations, or understandings, either oral or
written, between the PARTIES relating to the subject matter hereof. 

 IN WITNESS WHEREOF, WRF and
GLOBEIMMUNE have executed this AGREEMENT, in duplicate originals by their respective officers hereunto duly authorized, on the date hereinafter written. 

  
 Page 11

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

									
	GLOBEIMMUNE	 		 	WASHINGTON RESEARCH FOUNDATION
					
	By:	 	 /s/ Timothy C. Rodell, M.D.
	 		 	By:	 	 /s/ Beth G. Etscheid, Ph.D.

					
	Name:	 	Timothy C. Rodell, M.D.	 		 	Name:	 	 Beth G. Etscheid, Ph.D.

					
	Title:	 	Chief Executive Officer	 		 	Title:	 	 Director of Licensing

					
	Date:	 	 November 24, 2003
	 		 	Date:	 	 November 20, 2003

  
 Page 12

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 SUMMARY TABLE 

PAYMENTS 
  

							
	 Description
	  	Amount	  	Paragraph	  	Due Date
				
	 [*]
	  		  		  	

 REPORTS FROM GLOBEIMMUNE 

 

					
	 Description
	  	 Source
	    	 Due Date

			
	Progress	  	Paragraph 4.2	    	On or before March 1, annually
	SALES	  	Paragraph 4.2	    	 On or before March 1 and

September 1 of each year

	Date of First SALE of new LICENSED PRODUCT	  	Paragraph 4.2	    	Within 60 days of its occurrence
	Infringement Information	  	Article 6	    	Promptly
	Certificates of Insurance	  	Article 10	    	Annually

 REPORTS FROM WRF 
  

					
	 Description
	  	Source	    	 Due Date

			
	Patent Status	  	Paragraph 4.3	    	Within sixty (60) days of changes to the status

  
 Page 13

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 APPENDIX A 

 

													
	 Country
	  	Patent
App. No.	  	Filing
Date	  	Status	  	Patent
Number	  	Issue
Date	  	Expiry
Date
	 [*]
	  		  		  		  		  		  	

  
 Page 14

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 APPENDIX B 

GLOBEIMMUNE REPORT 
 Reporting Period:                      to
                     
  

																	
	 LICENSED PRODUCT
	  	Amount
Produced,
Imported
and
Inventoried	  	Country	  	Gross
Receipts	  	Currency	  	Exchange
Rate	  	Net
Sales	  	Royalty
Rate	  	Royalty
		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  	
		  		  		  		  		  		  		  		  	

 TOTALS 

EXCHANGE RATES USED: 
 NAMES AND
ADDRESSES OF AFFILIATES: 
  

									
	Signed:	 	  
	  	(GLOBEIMMUNE’S responsible financial officer)	  	
	Title:	 	  
	  		  		  	
	Dated:	 	  
	  		  		  	

  
 Page 15Amendment to the Field-Of-Use Non-Exclusive License Agreement

 Exhibit 10.11.1 
 [*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934,
as amended. 
 Execution Version 
 Amendment to the 
 Field-Of-Use Non-Exclusive License Agreement

 for Yeast-Based Delivery Vehicles 
 Between 
 Washington Research Foundation 

and 

GlobeImmune, Inc. 
 This Amendment to Field-Of-Use Non-Exclusive License Agreement For Yeast-Based Delivery Vehicles Between Washington Research Foundation and GlobeImmune, Inc. (the “Amendment”) is entered into by
Washington Research Foundation (“WRF”), a non-profit Washington Corporation, having administrative offices at 2815 Eastlake Avenue East, Suite 300, Seattle, Washington U.S.A. 98102, and GlobeImmune, Inc. (“GLOBEIMMUNE”), a
corporation organized under the laws of Delaware, having its principal office at 1450 Infinite Drive, Louisville, CO 80027, and is effective as of the day of the last of the PARTIES to sign (the “Amendment Date”). 

WHEREAS, WRF and GLOBEIMMUNE are PARTIES to a Field-Of-Use Non-Exclusive License Agreement For Yeast-Based Delivery Vehicles Between
Washington Research Foundation and GlobeImmune, Inc. (“AGREEMENT”), effective November 24, 2003, pertaining to recombinant yeast expression technology; 
 WHEREAS, GLOBEIMMUNE has requested an amendment to the AGREEMENT to (a) allow for SUBLICENSEES to have a right to grant sublicense rights under the PATENT RIGHTS, and (b) allow for SUBLICENSEES
to maintain rights to the TECHNOLOGY and PATENT RIGHTS in the event of the termination of the AGREEMENT due to a breach of the AGREEMENT by GLOBEIMMUNE; and 
 WHEREAS, WRF is willing to make such rights available to SUBLICENSEES. 
 NOW,
THEREFORE, the PARTIES agree to amend the AGREEMENT as follows. 
 Amendment 

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the PARTIES agree as follows:

 Capitalized terms used herein but not defined herein shall have the definitions set forth in the AGREEMENT. 

  
 1 

 [*] = Certain confidential information contained in this document, marked by brackets,
is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Paragraph 1.2 of the AGREEMENT will be deleted and replaced in its entirety with the
following: 
 “AFFILIATE” shall mean (i) any corporation or other business entity of which fifty percent
(50%) or more of the equity or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by GLOBEIMMUNE or a
SUBLICENSEE, as applicable; or (ii) any corporation, firm, partnership or other entity, whether de jure or de facto, which directly or indirectly owns, controls or holds fifty percent (50%) (or such lesser percentage that is the maximum
allowed to be owned by a foreign corporation in a particular jurisdiction) or more of the equity or profits, the voting stock or the general partnership interest, of GLOBEIMMUNE or a SUBLICENSEE, as applicable; or
(iii) any corporation or other business entity of which fifty percent (50%) or more of the equity or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held,
directly or indirectly, by a corporation or other business entity described in (i) or (ii), and any person, firm, partnership, corporation or other entity, including joint ventures or joint businesses, actually controlled by, controlling or
under common control with GLOBEIMMUNE or a SUBLICENSEE, as applicable. 
 Paragraph 1.8 of the AGREEMENT will be
deleted and replaced in its entirety with the following: 
 “SUBLICENSE” shall mean any agreement which includes the
present, future, or contingent transfer to a THIRD PARTY by GLOBEIMMUNE or a SUBLICENSEE under this AGREEMENT of a right under the PATENT RIGHTS in the FIELD OF USE to make, have made, use, offer for sale, sell, have
sold, import, or otherwise distribute LICENSED PRODUCT. A SALE is not a SUBLICENSE. 
 The second sentence of Paragraph 2.3
of the AGREEMENT will be deleted and replaced in its entirety with the following: 
 SUBLICENSEES shall have the right to
grant further SUBLICENSES under the PATENT RIGHTS in the FIELD OF USE. 
 The second sentence of Paragraph 3.7 of the
AGREEMENT will be deleted and replaced in its entirety with the following: 
 NET SALES received by
GLOBEIMMUNE, AFFILIATES or SUBLICENSEES in U.S. Dollars will not be the subject of currency conversion. 

  
 2 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 Paragraph 7.5 of the AGREEMENT will be deleted and replaced in its entirety with the
following: 
 Failure of either PARTY to comply with any of the material obligations contained in this AGREEMENT shall entitle
the other PARTY to give the breaching PARTY a notice specifying the nature of the breach claimed and the action required to correct the breach. If such breach is not corrected within [*] after the receipt of such notice, the notifying PARTY shall be
entitled, without prejudice to any of its other rights conferred on it by this AGREEMENT, in addition to any other remedies available to it by law, to terminate this AGREEMENT by giving written notice to the breaching PARTY effective immediately
upon receipt. In the event that WRF provides any notice of a breach and/or notice of a termination of this AGREEMENT under this Paragraph 7.5, WRF shall contemporaneously provide a copy of any such notice to any SUBLICENSEE of
GLOBEIMMUNE at the address set forth in the applicable notice provision of the applicable SUBLICENSE. 
 Paragraph 7.7 of the AGREEMENT will be deleted and replaced in its entirety with the following: 
 Any SUBLICENSES entered into by GLOBEIMMUNE shall terminate on the termination of this AGREEMENT pursuant to Paragraph 7.3, 7.4 or 7.5. Notwithstanding the foregoing, upon
termination of this AGREEMENT pursuant to Paragraph 7.3, 7.4 or 7.5, any SUBLICENSEE of GLOBEIMMUNE shall automatically become a direct licensee of WRF with respect to the rights sublicensed to the SUBLICENSEE by
GLOBEIMMUNE from the effective date of such termination on the terms of this AGREEMENT with all instances of “GLOBEIMMUNE” in this AGREEMENT deemed to be such SUBLICENSEE with
respect to the rights sublicensed to the SUBLICENSEE by GLOBEIMMUNE; provided that such SUBLICENSEE, as a condition of receiving such SUBLICENSE from GLOBEIMMUNE, (a) agrees to assume
all of GLOBEIMMUNE’s future obligations with respect to the rights sublicensed to the SUBLICENSEE by GLOBEIMMUNE after becoming such direct licensee, to the extent relating to the
activities of such SUBLICENSEE, (b) agrees to correct, and does correct, within ninety (90) days after becoming such direct licensee, any and all of GLOBEIMMUNE’s uncured breaches under Paragraphs 3.2
through 3.9 and uncured breaches with respect to financial reports under Paragraph 4.2 as of the effective date of such termination to the extent such breach resulted in such termination of this AGREEMENT and relates to the activities of such
SUBLICENSEE, which correction shall include paying any and all such amounts owed under such paragraphs that GlobeImmune has not paid to WRF as of the effective date of such termination to the extent such breach resulted in such termination of this
AGREEMENT and relates to the activities of such SUBLICENSEE, and (c) agrees to pay, and does pay, within ninety (90) days after receiving notice of such termination, any and all out-of-pocket costs and reasonable legal fees payable by
GLOBEIMMUNE to WRF under Paragraph 18 to 

  
 3 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 
the extent that GLOBEIMMUNE has not paid such amount and to the extent such costs and fees were incurred in an arbitration or legal action under Paragraph 18 that
resulted in such termination of this AGREEMENT and relates to the activities of such SUBLICENSEE; provided that such Sublicensee shall not be obligated to pay more than [*] in the aggregate under this Paragraph 7.7(c). For clarity, in the event of
any failure of such SUBLICENSEE to comply with the foregoing proviso or upon SUBLICENSEE’s election not to take a direct license, including without limitation by failing to cure any such failure or default of
GLOBEIMMUNE, such SUBLICENSEE shall not be deemed in breach of this AGREEMENT, and such SUBLICENSEE shall not have become a direct licensee of WRF in accordance with the foregoing sentence. 

Paragraph 8.2 of the AGREEMENT will be deleted and replaced in its entirety with the following: 

Upon the termination of this AGREEMENT, GLOBEIMMUNE shall inform WRF of the amount of LICENSED PRODUCTS
manufactured, imported or inventoried by GLOBEIMMUNE, AFFILIATES and SUBLICENSEES on or before the termination date. With respect to such manufactured, imported or inventoried LICENSED PRODUCTS,
GLOBEIMMUNE, AFFILIATES and SUBLICENSEES shall be permitted to make SALES after termination of this AGREEMENT and GLOBEIMMUNE shall pay WRF the earned royalty on these NET SALES, as
required under Section 3.2. Notwithstanding the foregoing, if GLOBEIMMUNE does not pay any and all earned royalties payable pursuant to the foregoing sentence with respect to any such manufactured, imported or
inventoried LICENSED PRODUCTS that are sold under a SUBLICENSE between GLOBEIMMUNE and a SUBLICENSEE, such SUBLICENSEE of GLOBEIMMUNE shall have the right to make SALES of LICENSED PRODUCTS
pursuant to the foregoing sentence only if such SUBLICENSEE agrees to pay, and does pay, within [*] after receiving notice of GLOBEIMMUNE’s failure to pay any such earned royalties, any and all such earned
royalties that GLOBEIMMUNE has not paid to WRF. 
 Paragraph 8.3 of the AGREEMENT will be
deleted and replaced in its entirety with the following: 
 Only the following Articles shall survive termination of this
AGREEMENT: 1, 3.2 (with respect to royalties accrued and unpaid as of termination of this AGREEMENT or due under Paragraph 8.2), 3.7, 3.8, 4, 5, 7.2, 7.7, 8, 10, 11, 14, 15, 16, 17, 18, 19, 20, and 21. 

The last sentence of Paragraph 11.1 of the AGREEMENT will be deleted and replaced in its entirety with the following: 

The use of the names Washington Research Foundation, WRF, University of Washington, or GENENTECH by
GLOBEIMMUNE, AFFILIATES and SUBLICENSEES is expressly prohibited. 

  
 4 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 The name and address line of Appendix B of the AGREEMENT will be deleted and replaced in
its entirety with the following: 
 NAMES AND ADDRESS OF AFFILIATES AND SUBLICENSEES: 

Except as expressly amended by this Amendment, all terms and conditions of the AGREEMENT remains in full force and effect. 

In the event of any conflict between the terms of the Agreement and this Amendment, the terms of this Amendment shall govern. 

[Signature Page Follows] 

  
 5 

 [*] = Certain confidential information contained in this document, marked by brackets, is filed with
the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 In witness whereof, both WRF and GLOBEIMMUNE have executed this Amendment, in duplicate
originals, by their respective officers hereunto duly authorized, on the day and year hereinafter written. 
  

									
	Washington Research Foundation	 		 	GlobeImmune, Inc.
					
	By:	 	 /s/ Beth G. Etscheid, Ph.D.
	 		 	By:	 	 /s/ Timothy C. Rodell, M.D.

					
	Printed:	 	Beth G. Etscheid, Ph.D.	 		 	Printed:	 	Timothy C. Rodell, M.D.
					
	Title:	 	Director of Licensing	 		 	Title:	 	President and CEO
					
	Date:	 	 May 4, 2009
	 		 	Date:	 	 May 5, 2009

 [Signature Page to Amendment to Field-Of-Use Non-Exclusive License Agreement For 

Yeast-Based Delivery Vehicles Between Washington Research Foundation and 

GlobeImmune, Inc.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]